A Phase 1 interventional study of BGJ398 in Tumor With Alterations of the FGF-R, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate safety and tolerability to determine the Maximum tolerated dose (MTD) and/or Recommended dose (RD).
This is a multi-center, open label, dose finding, phase I study of oral single agent BGJ398, administered on a continuous once and/or twice daily schedule.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants received oral BGJ398 once daily or twice daily. Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease.
Drug: BGJ398
Incidence rate and category of dose limiting toxicities (DLTs)
Maximum tolerated dose (MTD) and/or Recommended dose (RD) of single agent oral BGJ398
Time frame: First cycle of 28 days
Frequency of all Adverse Events (AEs) and Serious Advers Events (SAEs)
To characterize the safety and tolerability of oral BGJ398
Time frame: From within 21 days of first treatment to 28 days after treatment discontinuation
Changes in hematology and chemistry values
hematology and chemistry values
Time frame: From baseline to 28 days after treatment discontinuation
Assessments of physical examinations, vital signs and electrocardiograms (ECGs)
Time frame: Participants will be followed for the duration of treatment, an expected average of 24 weeks.
Time vs. concentration profiles
To determine the pharmacokinetic (PK) profiles (Cmax, AUC, Tmax, T1/2, etc) of oral BGJ398 including known pharmacologically active metabolites
Time frame: 1 to 10 time points (0, 0.25, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose) up to 24 weeks
Preliminary anti-tumor activity
Assessed based on RECIST version 1.1
Time frame: Participants will be followed for the duration of treatment, an expected average of 24 weeks.
Best overall response (BOR)
Assessed by investigator per RECIST version 1.1. BOR is the best response recorded until disease progression.
Time frame: Participants will be followed for the duration of treatment, an expected average of 24 weeks.
Overall response rate (ORR)
Assessed by investigator per RECIST version 1.1. ORR is the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR).
Time frame: Participants will be followed for the duration of treatment, an expected average of 24 weeks.
Progression-free survival (PFS)
PFS is defined as the times from the date of first dose of BGJ398 to the date of the first documented disease progression, date of death due to any cause or until a new anticancer therapy is initiated, whichever occurs first.
Time frame: From date of end of treatment until the date of progression, or date of death, or starting date of a new anticancer therapy, assessed up to 100 months.
Duration of all Adverse Events (AEs)
To characterize the safety and tolerability of oral BGJ398
Time frame: From within 21 days of first treatment to 28 days after treatment discontinuation
Duration of Serious Advers Events (SAEs)
To characterize the safety and tolerability of oral BGJ398
Time frame: From within 21 days of first treatment to 28 days after treatment discontinuation
Severity of all Adverse Events (AEs)
To characterize the safety and tolerability of oral BGJ398
Time frame: From within 21 days of first treatment to 28 days after treatment discontinuation
Severity of all Serious Advers Events (SAEs)
To characterize the safety and tolerability of oral BGJ398
Time frame: From within 21 days of first treatment to 28 days after treatment discontinuation
Plan to share: No
Ran from Oct 2012 to primary completion in Feb 2019, 75 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infigratinib